U.S. flag

An official website of the United States government

NM_000642.3(AGL):c.1183C>T (p.Gln395Ter) AND Glycogen storage disease type III

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Apr 28, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003634292.2

Allele description [Variation Report for NM_000642.3(AGL):c.1183C>T (p.Gln395Ter)]

NM_000642.3(AGL):c.1183C>T (p.Gln395Ter)

Gene:
AGL:amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1p21.2
Genomic location:
Preferred name:
NM_000642.3(AGL):c.1183C>T (p.Gln395Ter)
HGVS:
  • NC_000001.11:g.99875254C>T
  • NG_012865.1:g.30171C>T
  • NM_000028.3:c.1183C>T
  • NM_000642.3:c.1183C>TMANE SELECT
  • NM_000643.3:c.1183C>T
  • NM_000644.3:c.1183C>T
  • NM_000646.3:c.1135C>T
  • NM_001425325.1:c.1183C>T
  • NM_001425326.1:c.1183C>T
  • NM_001425328.1:c.979C>T
  • NM_001425329.1:c.979C>T
  • NM_001425332.1:c.805C>T
  • NP_000019.2:p.Gln395Ter
  • NP_000019.2:p.Gln395Ter
  • NP_000633.2:p.Gln395Ter
  • NP_000634.2:p.Gln395Ter
  • NP_000634.2:p.Gln395Ter
  • NP_000635.2:p.Gln395Ter
  • NP_000635.2:p.Gln395Ter
  • NP_000637.2:p.Gln379Ter
  • NP_000637.2:p.Gln379Ter
  • NP_001412254.1:p.Gln395Ter
  • NP_001412255.1:p.Gln395Ter
  • NP_001412257.1:p.Gln327Ter
  • NP_001412258.1:p.Gln327Ter
  • NP_001412261.1:p.Gln269Ter
  • NC_000001.10:g.100340810C>T
  • NM_000028.2:c.1183C>T
  • NM_000643.2:c.1183C>T
  • NM_000644.2:c.1183C>T
  • NM_000646.2:c.1135C>T
Protein change:
Q269*
Molecular consequence:
  • NM_000028.3:c.1183C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_000642.3:c.1183C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_000643.3:c.1183C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_000644.3:c.1183C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_000646.3:c.1135C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001425325.1:c.1183C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001425326.1:c.1183C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001425328.1:c.979C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001425329.1:c.979C>T - nonsense - [Sequence Ontology: SO:0001587]
  • NM_001425332.1:c.805C>T - nonsense - [Sequence Ontology: SO:0001587]

Condition(s)

Name:
Glycogen storage disease type III (GSD3)
Synonyms:
Glycogen storage disease type 3; Forbes disease; Cori disease; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009291; MedGen: C0017922; Orphanet: 366; OMIM: 232400

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV004551480Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Apr 28, 2023)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Distinct mutations in the glycogen debranching enzyme found in glycogen storage disease type III lead to impairment in diverse cellular functions.

Cheng A, Zhang M, Okubo M, Omichi K, Saltiel AR.

Hum Mol Genet. 2009 Jun 1;18(11):2045-52. doi: 10.1093/hmg/ddp128. Epub 2009 Mar 19.

PubMed [citation]
PMID:
19299494
PMCID:
PMC2678930

Distinct Clinical and Genetic Findings in Iranian Patients With Glycogen Storage Disease Type 3.

Nazari F, Sinaei F, Nilipour Y, Petit F, Oveisgharan S, Nassiri-Toosi M, Razzaghy-Azar M, Mahmoudi M, Nafissi S.

J Clin Neuromuscul Dis. 2018 Jun;19(4):203-210. doi: 10.1097/CND.0000000000000212.

PubMed [citation]
PMID:
29794575
See all PubMed Citations (3)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV004551480.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

This sequence change creates a premature translational stop signal (p.Gln395*) in the AGL gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in AGL are known to be pathogenic (PMID: 19299494). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This premature translational stop signal has been observed in individual(s) with glycogen storage disease (PMID: 29794575). This variant is not present in population databases (gnomAD no frequency).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024